Obesity - Pipeline Review, H1 2020

May 2020 | 592 pages | ID: O1850A4EB5FEN
Global Markets Direct

Abstracts

Obesity - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity – Pipeline Review, H1 2020, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.

Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obesity – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 4, 21, 29, 4, 118, 38 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 53 and 10 molecules, respectively.

Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Obesity - Overview
Obesity - Therapeutics Development
Obesity - Therapeutics Assessment
Obesity - Companies Involved in Therapeutics Development
Obesity - Drug Profiles
Obesity - Dormant Projects
Obesity - Discontinued Products
Obesity - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Obesity, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Obesity - Pipeline by Aardvark Therapeutics Inc, H1 2020
Obesity - Pipeline by Adare Pharmaceuticals Inc, H1 2020
Obesity - Pipeline by Adipo Therapeutics LLC, H1 2020
Obesity - Pipeline by Adocia SAS, H1 2020
Obesity - Pipeline by AgeX Therapeutics Inc, H1 2020
Obesity - Discontinued Products, H1 2020
Obesity - Discontinued Products, H1 2020 (Contd..1), H1 2020
Obesity - Discontinued Products, H1 2020 (Contd..2), H1 2020
Obesity - Discontinued Products, H1 2020 (Contd..3), H1 2020
Obesity - Discontinued Products, H1 2020 (Contd..4), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Obesity, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Aardvark Therapeutics Inc
Adare Pharmaceuticals Inc
Adipo Therapeutics LLC
Adocia SAS
AgeX Therapeutics Inc
Akero Therapeutics Inc
Alla Chem LLC
Altimmune Inc
Amgen Inc
Antag Therapeutics ApS
Aoxing Pharmaceutical Company Inc
Applied Molecular Transport LLC
AptamiR Therapeutics Inc
Aptorum Group Ltd
Armata Pharmaceuticals Inc
AstraZeneca Plc
Athersys Inc
Auris Medical Holding Ltd
Betagenon AB
BioRestorative Therapies Inc
Biozeus Pharmaceutical SA
Boehringer Ingelheim International GmbH
Braasch Biotech LLC
Bukwang Pharm Co Ltd
Caliway Biopharmaceutics Co Ltd
Callitas Therapeutics Inc
Can-Fite BioPharma Ltd
Carmot Therapeutics Inc
Cellivery Therapeutics Inc
Celon Pharma SA
Centeer BioTherapeutics Ltd Co
Chong Kun Dang Pharmaceutical Corp
CohBar Inc
Corbus Pharmaceuticals Inc
Corcept Therapeutics Inc
Curacle Co Ltd
D&D Pharmatech Co Ltd
DD Therapeutics LLC
Diasome Pharmaceuticals Inc
DiscoveryBiomed Inc
Eli Lilly and Co
Empros Pharma AB
EncuraGen Inc
Eolo Pharma
EraCal Therapeutics AG
Eternygen GmbH
Evecxia Inc
FGH BioTech Inc
Gila Therapeutics Inc
Gilead Sciences Inc
Glaceum Inc
Glucox Biotech AB
Gmax Biopharm Ltd
Gubra ApS
HanAll Biopharma Co Ltd
Hangzhou Adamerck Pharmlabs Inc
Hanmi Pharmaceuticals Co Ltd
Helsinn Group
Immune Biosolutions Inc
Immungenetics AG
Infusion Biosciences
Innovimmune Biotherapeutics Inc
Intarcia Therapeutics Inc
Japan Tobacco Inc
Jenrin Discovery Inc
Johnson & Johnson
Juno Therapeutics Inc
Kallyope Inc
KinDex Pharmaceuticals Inc
Kintai Therapeutics Inc
Kissei Pharmaceutical Co Ltd
KoBioLabs Inc
Kriya Therapeutics
Lead Discovery Center GmbH
LG Chem Ltd
Lipidio Pharmaceuticals Inc
Living Cell Technologies Ltd
Lixte Biotechnology Holdings Inc
LNC Therapeutics SA
Lobesity LLC
Lynkogen Inc
MAKScientific LLC
MD Healthcare Inc
Merck & Co Inc
Mirabilis Therapeutics BV
Nano Intelligent Biomedical Engineering Corp
NeuroNano Pharma Inc
NGM Biopharmaceuticals Inc
Nordic Bioscience AS
Novartis AG
NovMetaPharma Co Ltd
Novo Nordisk AS
Nubiyota LLC
NuSirt Biopharma Inc
ObeTherapy Biotechnology
Omeros Corp
Onegene Biotechnology Inc
OPKO Health Inc
Oramed Pharmaceuticals Inc
Orbit Discovery Ltd
Oxt Therapeutics Inc
Palatin Technologies Inc
PegBio Co Ltd
Pfizer Inc
Poxel SA
Preveceutical Medical Inc
Raziel Therapeutics
Regeneron Pharmaceuticals Inc
Renova Therapeutics Inc
Reviva Pharmaceuticals Inc
Rhamnopharma Inc
Rhythm Pharmaceuticals Inc
Saniona AB
Sanofi
Scioto Biosciences Inc
Scohia Pharma Inc
Seres Therapeutics Inc
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shionogi & Co Ltd
Sigrid Therapeutics AB
Siragen Pharmaceuticals Inc
SJT Molecular Research SL
Soleno Therapeutics Inc
Symmetry Therapeutics Inc
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Talapo Therapeutics Inc
Techfields Pharma Co Ltd
Ube Industries Ltd
Uni-Bio Science Group Ltd
Velabs Therapeutics GmbH
Virtici LLC
Vivus Inc
XL-protein GmbH
Yuhan Corp
Zealand Pharma AS
Zhejiang Doer Biologics Corp
Zihipp Ltd